170571-20-7

Basic information

• Product Name: METHYL 1-[4-(AMINOSULFONYL)PHENYL]-5-(4-CHLOROPHENYL)-1H-PYRAZOLE-3-CARBOXYLATE
• Synonyms: METHYL 1-[4-(AMINOSULFONYL)PHENYL]-5-(4-CHLOROPHENYL)-1H-PYRAZOLE-3-CARBOXYLATE;Methyl-1-[4-(Aminosulfonyl)Phenyl]-5-(4-Chlorophenyl)-1H-Pyrazole-3-Carboxylate(WXC03166)
• CAS NO: 170571-20-7
• Molecular Formula: C₁₇H₁₄ClN₃O₄S
• Molecular Weight: 391.83
• Mol File: 170571-20-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: METHYL 1-[4-(AMINOSULFONYL)PHENYL]-5-(4-CHLOROPHENYL)-1H-PYRAZOLE-3-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 1-[4-(AMINOSULFONYL)PHENYL]-5-(4-CHLOROPHENYL)-1H-PYRAZOLE-3-CARBOXYLATE(170571-20-7)
• EPA Substance Registry System: METHYL 1-[4-(AMINOSULFONYL)PHENYL]-5-(4-CHLOROPHENYL)-1H-PYRAZOLE-3-CARBOXYLATE(170571-20-7)

Safety Data

• Hazardous Substances Data: 170571-20-7(Hazardous Substances Data)

Upstream product

• 553-90-2 Dimethyl oxalate 
• 99-91-2 para-chloroacetophenone 
• 4392-54-5 4-aminosulfonylphenylhydrazine 
• 37542-28-2 methyl (p-chlorphenyl)glyoxylate 
• 124-41-4 sodium methylate 
• 39757-35-2 methyl 4-(4-chlorophenyl)-2,4-dioxobutanoate 
• 17852-52-7 4-hydrazinobenzene-1-sulfonamide hydrochloride 

Downstream Products

• 170571-19-4 1-[4-(aminosulfonyl)phenyl]-5-(4-chlorophenyl)-1H-pyrazole-3-carboxylic acid 
• 170572-00-6 [1-(4-aminosulfonylphenyl)-4-chloro-5-(4-chlorophenyl)-1H-pyrazol-3-yl]carboxamide 
• 170572-05-1 [1-(4-aminosulfonylphenyl)-4-chloro-5-(4-chlorophenyl)-1H-pyrazol-3-yl]carboxylic acid 
• 170570-50-0 4-[5-(4-chlorophenyl)-3-(cyanomethyl)-1H-pyrazol-1-yl]benzenesulfonamide 
• 170571-48-9 4-[5-(4-chlorophenyl)-3-(chloromethyl)-1H-pyrazol-1-yl]benzenesulfonamide 
• 170571-71-8 4-[5-(4-chlorophenyl)-3-(3-hydroxymethyl)-1H-pyrazol-1-yl]benzenesulfonamide 
• 170569-75-2 methyl [1-(4-aminosulfonylphenyl)-4-chloro-5-(4-chlorophenyl)-1H-pyrazol-3-yl]carboxylate 

Relevant articles and documents

Discovery of novel sulfonamide-containing aminophosphonate derivatives as selective COX-2 inhibitors and anti-tumor candidates

As an essential enzyme with a variety of physiological functions, Cyclooxygenase-2 (COX-2) is also closely related to carcinoma due to the observed overexpression. In this work, a novel series of sulfonamide-containing aminophosphonate derivatives (A1-A25

Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use

The present invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or optionally, at least one therapeutic agent, such as, steroids, nonsteroidal antiinflammatory compounds (NSAID), 5-lipoxygenase (5-LO) inhibitors, leukotriene B4 (LTB4) receptor antagonists, leukotriene A4 (LTA4) hydrolase inhibitors, 5-HT agonists, 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) inhibitors, H antagonists, antineoplastic agents, antiplatelet agents, decongestants, diuretics, sedating or non-sedating anti-histamines, inducible nitric oxide synthase inhibitors, opioids, analgesics, Helicobacter pylori inhibitors, proton pump inhibitors, isoprostane inhibitors, and mixtures thereof. The present invention also provides novel compositions comprising at least one parent COX-2 inhibitor and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The present invention also provides kits and methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 inhibitors; for facilitating wound healing; for treating and/or preventing renal toxicity; and for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2.

Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation

A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: STR1 or a pharmaceutically-acceptable salt thereof.